Latest Breaking News On - Shankar musunuri - Page 14 : comparemela.com

Ocugen to Present at BIO International Convention 2023

MALVERN, Pa., May 23, 2023 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced. | May 23, 2023

United statesShankar musunuriQuan vuBoston conventionInternational conventionExchange commissionExhibition centerOcugen incChief executive officerChief financial officerChief businessPrivate securities litigation reform actNc stock exchangePress releaseOday ocgn us67577c1053

Ocugen Provides Business Update with First Quarter 2023 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber. | May 5, 2023

United statesShankar musunuriOcugen incExchange commissionHead of communicationsConference callWebcast todayPositive preliminary safetyEfficacy resultsRetinitis pigmentosaLeber congenital amaurosisOrphan drug designationAssociated retinopathies including stargardtCone rod dystrophyMultiple proposalsFederal funding

Ocugen (OCGN) Q1 2023 Earnings Call Transcript

OCGN earnings call for the period ending March 31, 2023.

United statesJennifer kim cantor fitzgeraldQuan vuShankar musunuriSwayampakula ramakanthJonathan aschoffRobert leboyerDaniil gataulinJennifer kimDaniil gataulin chardanSwayampakula hc wainwrightSharon choeShankar musunuri coDrug administrationCompany analystCantor fitzgerald

Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies

U.S. Food & Drug Administration grants orphan drug designation to OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt, RP19 and CORD3MALVERN, Pa., April 27, 2023 . | April 27, 2023

United statesShankar musunuriUs food drug administrationExchange commissionOcugen incNuclear hormone receptors nhrsDrug administrationOrphan drug designationRetinitis pigmentosaOrphan receptorNuclear hormone receptorsPrivate securities litigation reform actNc stock exchangePress release023 ocgn us67577c1053

Ocugen (OCGN) Receives Orphan Drug Designation for OCU410ST

Ocugen (OCGN) Receives Orphan Drug Designation for OCU410ST
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesShankar musunuriHead of communicationsNuclear hormone receptors nhrsOcugen incExchange commissionWall streetOrphan drug designationRetinitis pigmentosaOrphan receptorNuclear hormone receptorsPrivate securities litigation reform act